Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review

INTRODUCTION: Chronic myelogenous leukemia (CML) is a progressive and often fatal hematopoietic neoplasm. The Bcr-Abl tyrosine kinase inhibitor imatinib mesylate represented a major therapeutic advance over conventional CML therapy, with more than 90% of patients obtaining complete hematologic respo...

Full description

Saved in:
Bibliographic Details
Main Authors: Jabbour, Elias, Cortes, Jorge, Kantarjian, Hagop
Format: Artigo
Language:Inglês
Published: Dove Medical Press 2010
Subjects:
Review
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2899790/
https://ncbi.nlm.nih.gov/pubmed/20694077
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items